Aflatoxin exposure is associated with an increased risk of gallbladder cancer
International Journal of Cancer · 2025
DOI: 10.1002/ijc.35171 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Amit Yadav und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, PGIMER, Chandigarh, India. Hauptthemen laut MEDLINE: Gallbladder Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Gall bladder cancer (GBC) is common among the socioeconomically deprived populations of certain geographical regions. Aflatoxin is a genotoxic hepatocarcinogen, which is recognized to have a role in the pathogenesis of hepatocellular carcinoma. However, the role of aflatoxin in the pathogenesis of GBC is largely unknown. We determined serum AFB1‐Lys albumin adduct (AAA) levels as a marker of aflatoxin exposure in the patients with GBC and compared to those without GBC. The relationship of AAA levels to cytogenetic (TP53mutation&HER2/neu amplification) and radiological characteristics of the tumor was assessed. We included GBC cases ( n = 51) and non‐GBC controls ( n = 100). Mean serum AAA levels were higher in the GBC group ( n = 51) than those without GBC ( n = 100) (26.1 ± 12.2 vs. 13.1 ± 11.9 ng/mL; p < .001). HER2/neu expression was associated with higher AAA levels compared to those with equivocal or negative expression (43.9 ± 3 vs. 28.6 ± 10 vs. 19.3 ± 7 ng/mL; p < .001). Older age (age >50 years) (odds ratio [OR] = 3.2 [CI: 1.3–8.2]; p = .013), positive Helicobacter pylori serology (OR = 5.1 [CI: 1.4–17.8]; p = .012), presence of GS (OR = 5 [CI: 1.5–16.9]; p = .009) and detectable AAA levels (OR = 6.8 [CI: 1.3–35.7]; p = .024) were independent risk factors for the presence of the GBC among all study subjects. Among patients harboring GS, older age (age >50 years) (OR = 4.5 [CI: 1.3–14.9]; p = .015), female gender (OR = 3.8 [CI: 1.2–12.5]; p = .027), presence of multiple GS (OR = 21.9 [CI: 4.8–100.4]; p < .001) and high serum AAA levels (OR = 5.3 [CI: 1.6–17.3]; p = .006) were independent risk factors for the presence of the GBC. Elderly age >50 years (OR = 2.6 [CI: 1.3–5.2]; p = .010) and frequent peanut consumption (OR = 2.3 [CI: 1.1–4.9]; p = .030) were independent risk factors for high serum AAA levels. The current study has implications for the prevention of GBC through the reduction of dietary aflatoxin exposure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, PGIMER, Chandigarh, India.
- Department of Radiology, PGIMER, Chandigarh, India.
- Department of Cytology & Gynecological Pathology, PGIMER, Chandigarh, India.
- Department of Clinical Pharmacology, PGIMER, Chandigarh, India.
- Department of Medical Oncology, PGIMER, Chandigarh, India.
- Department of Surgery, PGIMER, Chandigarh, India.
ORCID-Profile: Amit Yadav, Radhika Srinivasan, Usha Dutta
Zitieren
APA
Yadav, A., Gupta, P., Gupta, P., Patil, A. N., Das, C. K., Hooda, H., Thakur, D., Sharma, V., Singh, A. K., Yadav, T. D., Kaman, L., Thakur, J. S., Sudini, H. K., Srinivasan, R., & Dutta, U. (2025). Aflatoxin exposure is associated with an increased risk of gallbladder cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.35171
Vancouver
Yadav A, Gupta P, Gupta P, Patil AN, Das CK, Hooda H, et al. Aflatoxin exposure is associated with an increased risk of gallbladder cancer. International Journal of Cancer. 2025. doi:10.1002/ijc.35171
BibTeX
@article{Yadav2025,
author = {Yadav, Amit and Gupta, Pankaj and Gupta, Parikshaa and Patil, Amol N and Das, Chandan K and Hooda, Harish and Thakur, Deepa and Sharma, Vishal and Singh, Anupam K and Yadav, Thakur Deen and Kaman, Lileswar and Thakur, Jarnail Singh and Sudini, Hari Kishan and Srinivasan, Radhika and Dutta, Usha},
title = {Aflatoxin exposure is associated with an increased risk of gallbladder cancer},
journal = {International Journal of Cancer},
year = {2025},
doi = {10.1002/ijc.35171}
}
EUVIMED